Eugia Pharma Specialties’ manufacturing hub in India has received an FDA warning letter based on inspections of its facility. The new warning letter is tied to previous warnings about the company’s Unit III Formulation manufacturing facility. The unit makes terminally sterilized products. Eugia’s Hyderabad, India-based facility received an official action indicated (OAI) status notice in…